Glaukos Corp 2026 Investor Presentation: Key Developments and Strategic Outlook

Executive Summary

Glaukos Corp’s May 2026 Investor Presentation reveals a robust growth trajectory, significant pipeline advances, and strategic initiatives that could materially impact shareholder value. The company is positioned as an innovation leader in ophthalmology, targeting chronic eye diseases with pioneering pharmaceutical-device hybrids, and addressing major unmet clinical needs in glaucoma and keratoconus. Below, we detail the most important highlights, developments, and risks that investors must consider.

Key Highlights

• Industry-Leading Pipeline: Glaukos has disclosed 13 pipeline programs and currently commercializes 12 products, including iStent, iDose, Photrexa, and the newly launched Epioxa. This extensive portfolio underscores its commitment to innovation and market expansion.
• Significant Financial Growth: The company achieved 30% topline growth in 2025 and maintains a 20% compounded 10-year revenue growth. Over \$1 billion has been invested in R&D since 2018, supporting continued pipeline development and commercialization.
• Solid Financial Position: As of March 31, 2026, Glaukos holds \$281 million in cash and equivalents, with no debt, maintaining an 84% gross margin in Q1 2026. The company operates in 17 countries with direct infrastructure and boasts over 300 commercial personnel.

Strategic Product Updates

Glaucoma Therapies

• iDose TR: This long-duration drug therapy anchors securely in scleral tissue, delivering up to 3 years of highly concentrated travoprost. The device addresses patient non-compliance and is FDA-approved for repeat administration as of January 2026. New Phase 3 data demonstrates non-inferiority to topical timolol over three years, with 81% of subjects free of IOP-lowering topical medications at 12 months. Expansion of the iDose platform is underway, with TRIO and TREX versions in advanced clinical stages.
• iStent Infinite: Pioneered as a best-in-class MIGS (minimally invasive glaucoma surgery) therapy for long-term intraocular pressure control. Backed by 14 years of commercial leadership and 300+ peer-reviewed publications, it offers up to 240° outflow coverage. Ongoing studies aim to expand its label for broader patient groups.
• PRESERFLO MicroShunt: Approved outside the US for advanced-refractory glaucoma, with a US IDE study ongoing.

Keratoconus Therapies

• Epioxa: Launched in March 2026, Epioxa is the first and only FDA-approved epithelium-on treatment for keratoconus. It offers incision-free, topical drug therapy catalyzed by oxygen and light, designed for a single administration to slow or halt disease progression. Epioxa enables a streamlined procedure and faster recovery, improving patient access and experience.
• Photrexa: The only FDA-approved corneal cross-linking therapy since 2016; however, only 1 in 5 newly diagnosed progressive KC eyes currently access Photrexa, highlighting significant underdiagnosis and undertreatment.
• Next-Generation iLink: Customized, spherical therapy for KC is in Phase 2 clinical trials, leveraging biomechanical modeling to deliver patient-specific treatments, potentially revolutionizing KC care.

Novel Therapies and Platforms

• iLution Eyelid Drug Delivery Platform: Currently in Phase 2 development for Demodex blepharitis and progressive myopia. This transdermal cream offers easier administration, faster onset, fewer side effects, and improved patient compliance, targeting an estimated 25 million US patients and a \$400 million market.
• Retina XR Biodegradable Implants: Designed for long-duration efficacy in retinal diseases (AMD, DME, RVO), this small molecule implant aims to address the compliance and treatment burden of monthly or bi-monthly anti-VEGF injections. The lead candidate is in Phase 2a clinical trials, targeting a market of over 28 million US patients and \$10+ billion in annual sales.
• Radius XR Wearable Diagnostic System: FDA-cleared device for patient engagement and diagnostics.

Market and Clinical Insights

• Paradigm Shift in Glaucoma Care: Glaukos is leading a transition from compliance-dependent topical drops to proactive, personalized procedural pharmaceuticals, creating “forever patients” and enabling comprehensive ophthalmic practices to deliver continual care across the disease spectrum.
• Growth Opportunities: The company anticipates that by 2035, US ophthalmologists could perform as many interventional glaucoma procedures as cataract surgeries, driven by new sustained-release drug delivery products, combination therapies, and in-office injectable delivery.
• Keratoconus Underdiagnosis: Company analysis reveals vast underdiagnosis and undertreatment, with only a fraction of eligible patients receiving sight-saving therapy. Major payer hurdles, poor awareness, and fragmented patient journeys highlight the need for new standards of care and market access infrastructure.

Risks and Forward-Looking Statements

• Risks: The company faces risks including supply and manufacturing disruptions, cybersecurity threats, regulatory compliance costs, changes in healthcare laws, uncertainty of clinical trial outcomes, and intellectual property litigation. These risks could materially affect results and share value.
• Regulatory and Market Risks: Success depends on commercialization of new therapies (iDose TR, Epioxa), achieving payer coverage and reimbursement, and successful expansion of pipeline products. Delays or failures in clinical trials, market access, or regulatory approvals could impact profitability and valuation.
• Opportunities: Approval and adoption of new therapies, especially sustained-release implants and novel drug delivery platforms, could drive substantial revenue growth and market share expansion.

Conclusion

Glaukos Corp’s 2026 outlook is marked by strong financial performance, a deep and innovative product pipeline, and strategic moves to address major unmet clinical needs in ophthalmology. The launch of Epioxa, FDA approval of repeat iDose TR administration, and advances in sustained-release drug delivery technology represent potential inflection points for revenue growth and market leadership. Investors should monitor regulatory milestones, commercialization progress, and market adoption closely, as these developments are likely to be price sensitive and materially affect share values.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Investors are encouraged to review Glaukos Corp’s SEC filings and consult their financial advisors before making investment decisions.

View GLAUKOS Corp Historical chart here